Traitement en cours...
December 2012: XenTech Acknowledged in Deloitte’s 2012 Technology Fast 500™ EMEA for 2nd Year Running
Press Release: XenTech's human tumor xenograft platform honored by Deloitte
November 2012: XenTech builds up a kidney cancer PDX panel
XenTech is proud to announce the expansion of its patient-derived tumor xenograft collection with new renal carcinoma PDX models. Please contact us for more information.
October 2011: Paola Bazzacco hired as Business Development Manager
XenTech is pleased to announce that Paola Bazzacco recently joined its Business Development team.
September 2011: XenTech welcomes a Postdoctoral Research Fellow (Marie Curie Fellowship in Cancer Stem Cell Research)
Eurocancer Stemcell Training is a network gathering 9 laboratories of 6 member states at the highest level of cancer stem cell research. EuroCSC training offers the opportunity to young researchers to join an excellent training platform in this new area of Cancer Research.
Xentech is part of the network. [...] to know more
October 2010: XenTech expands its breast cancer PDX collection
XenTech is proud to announce the expansion of its breast cancer preclinical platform, with new models established at the Institut Curie. With 34 xenografts encompassing the major molecular subtypes of breast tumors, XenTech confirms its leadership in the field of breast cancer preclinical research.
May 2010: XenTech revamps its logo
As XenTech nears its 4th anniversary, it is time to revamp our brand image, to reflect the transition from the company’s launch status to a maturity stage. The new logo is in line with a series of changes that occurred during the last year: the appointment, in May 2009, of Bertrand Coulomb as CEO, the outstanding rise of our scientific and technical staff by nearly 60%, and, in February 2010, the arrival of Sabrina Serpillon as Business Development Manager. This new logo is simply a continuation of key steps in our development plan.
February 2010: Appointment of Sabrina Serpillon as Business Development Manager
XenTech announces the appointment of Sabrina Serpillon as Business Development Manager. Sabrina Serpillon will assume her new responsibilities in February 2010.
Since 2006, XenTech has experienced an outstanding growth, which, so far, has been relying only on its world-recognized scientific expertise and the high quality services it provides. Thanks to her scientific background in pharmacology and her previous experience in a Contract Research Organization (CRO), Sabrina will bring valuable skills to XenTech’s team and help achieving new exciting challenges.
May 2009: XenTech appoints Bertrand Coulomb as CEO
XenTech is pleased to announce the appointment of Bertrand Coulomb as Chief Executive Officer (CEO). Bertrand Coulomb will take up his new duties on May 2009. Bertrand’s coming represents a significant milestone for XenTech. The company’s rapid growth led to the need to bring in a CEO who would provide business and strategic vision and XenTech move forward. Bertrand Coulomb has more than two decades of experience in Pharmaceutical and Diagnostics industries and has held high level corporate management positions. He is the right person to take XenTech to the next level.
ExonHit : September 22nd, 2008
Essonne.fr : May 02nd, 2007
Nouvelles Economiques de Paris Ile de France : March 2007
L'Usine Nouvelle : February 15th, 2007
Genopole.com : February 1st, 2007